Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).

Whole-brain radiotherapy useful in seniors with small cell lung cancer with brain metastasis

28 Jun 2019

Whole-brain radiotherapy (WBRT) confers a slight survival benefit for elderly small cell lung cancer (SCLC) patients with brain metastasis unfit for chemotherapy, a recent study has shown.

Of the 1,615 enrolled SCLC patients (age 75 years; 51 percent female), 576 received both chemotherapy and WBRT, 238 received chemotherapy alone and 360 were given WBRT alone. The remaining 441 patients did not receive any treatment.

In patients not on chemotherapy, median overall survival (OS) was modestly but significantly higher in those who did vs did not receive WBRT (1.9 vs 1.2 months; p<0.0001). Multivariable Cox regression analysis further confirmed the survival benefit of WBRT (hazard ratio [HR], 0.71, 95 percent CI, 0.61–0.82; p<0.0001).

Increasing age, on the other hand, was revealed to be a significant risk factor for death in the no-chemotherapy group (HR, 1.17, 1.01–1.35; p=0.0336).

In those who were receiving chemotherapy, on the other hand, WBRT did not seem to play an important role in survival. Median OS in those with vs without WBRT were 5.6 and 6.4 months, respectively (p=0.43).

Multivariable Cox regression analysis identified age >80 years (HR, 1.34, 1.15–1.57; p=0.0002), extracranial metastasis (HR, 1.30, 1.12–1.50), the male sex (HR for females, 0.85, 0.74–0.99; p=0.028) and rural location (HR, 1.94, 1.13–3.31; p=0.014) as significant predictors of death. WBRT failed to reach significance (HR, 1.12; 0.95–1.32; p=0.18).

“[I]n patients without neurologic symptoms, the omission of WBRT in lieu of radiosurgery or palliative measures only might be considered in select patients,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

10 Mar 2017
The addition of pravastatin to standard chemotherapy does not improve outcomes in patients with small-cell lung cancer (SCLC), results of a study have shown.
Tristan Manalac, 03 Dec 2019
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).